TIETOJA TÄSTÄ PODCASTISTA 🔗

Keskimääräinen äänen pituus:
10 minutes
Englanti
Yhdysvallat
16 jaksoa
vuodesta 28. toukokuuta 2013
episodic

VIIMEISIN JAKSO 🔗

Prof Perou talks to ecancer reporter Peter Goodwin about the Cancer Genome Atlas; working to target drugs and improve treatment by forming a comprehensive picture of breast cancer biology. They also discuss an overview of biomarkers, pathways and inhibitors, drugs in the pipeline for PI3 Kinase an…

HAE EDELLISIÄ EPISODEJA

Hae kanavan IMPAKT 2013 vanhoja jaksoja.

EDELLISET JAKSOT

ecancer reporter Peter Goodwin talks to Dr Navin at the 2013 IMPAKT conference in Brussels about the new technology of single cell sequencing. Blood tests allow the sampling of CTCs and thus the genome of any primary and metastatic tumours; this then allows the progress of a tumour to be monitored…
Prof Caldas talks to ecancer reporter Peter Goodwin at IMPAKT 2013, May 2nd, in Brussels, about the sub types of breast cancer looked at in the METABRIC study on the molecular stratification of breast cancer; and the latest analysis of that data.
ecancer reporter Peter Goodwin talks to Dr Rosanna Lau about the contribution of analytical, pre-analytical and intra-tumoural heterogeneity to variance in gene expression measurements from human breast cancers. Her new study has revealed the clearest picture yet of precisely how much measurement …
orld-leading epidemiologist Prof Jack Cuzick talks to ecancer about his paper in the Lancet confirming that selective estrogen receptor modulators (SERMs) are both effective and safe for preventing breast cancer in women who are at high risk of the disease but who are not ill. There has been cauti…
ecancer reporter Peter Goodwin talks to Dr Yanina Dockx at the 2013 IMPAKT meeting in Brussels. Aberrant activation of the PI3K-Akt-mTOR pathway is an important driver of resistance to HER2 targeted therapies and is involved in glucose homeostasis. 18F-FDG-PET has been proposed for early response …
Prof Piccart talks to ecancertv at the 2013 IMPAKT meeting in Brussels about her assessment of genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer from the BOLERO-2 trial by next-generation sequencing. Prof Piccart also discusses the typ…
ecancer reporter Peter Goodwin talks to Dr Sara Hurvitz at IMPAKT 2013 in Brussels. What does the future hold for PI3K/AKT/mTOR inhibitors in breast cancer?
ecancer reporter Peter Goodwin talks to Dr Thordur Oskarsson of the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) at IMPAKT 2013 in Brussels. They discuss how the extracellular matrix proteins of stem cell niches promote breast cancer metastasis, and what implic…
ecancer reporter Peter Goodwin talks to Dr Carey at the 2013 IMPAKT conference in Brussels about redesigning drug trials in the genomic era. They discuss the different trial options available including neoadjuvant trials.
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin ecancer.org:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.